PT97770B

PT97770B - Metodo para o tratamento de doenca mental psicotica com uanidinas substituidas tendo elevada afinidade de ligacao ao receptor sigma

Metodo para o tratamento de doenca mental psicotica com uanidinas substituidas tendo elevada afinidade de ligacao ao receptor sigma Download PDF

Info

Publication number: PT97770B
Authority: PT; Portugal
Prior art keywords: guanidine; carbon atoms; tolyl; iodophenyl; exo
Prior art date: 1990-05-25

Application number

PT97770A

Other languages

English (en)

Portuguese (pt)

Other versions

PT97770A (pt

Inventor

Eckard Weber

John F W Keana

Original Assignee

Univ Oregon

Priority date

1990-05-25

Filing date

1991-05-24

Publication date

1998-10-30

1991-05-24 Application filed by Univ Oregon filed Critical Univ Oregon

1992-06-30 Publication of PT97770A publication Critical patent/PT97770A/pt

1998-10-30 Publication of PT97770B publication Critical patent/PT97770B/pt

Links

108010085082 sigma receptors Proteins 0.000 title claims description 91
238000000034 method Methods 0.000 title claims description 57
238000011282 treatment Methods 0.000 title claims description 30
208000028017 Psychotic disease Diseases 0.000 title claims description 22
208000020016 psychiatric disease Diseases 0.000 title claims description 7
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 215
229910052757 nitrogen Inorganic materials 0.000 claims description 184
-1 3,5-dimethyl-1-adamantyl Chemical group 0.000 claims description 130
150000001875 compounds Chemical class 0.000 claims description 107
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 105
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 105
230000027455 binding Effects 0.000 claims description 89
125000004432 carbon atom Chemical group C* 0.000 claims description 85
210000004556 brain Anatomy 0.000 claims description 55
150000002357 guanidines Chemical class 0.000 claims description 55
239000012528 membrane Substances 0.000 claims description 48
102000005962 receptors Human genes 0.000 claims description 45
108020003175 receptors Proteins 0.000 claims description 45
208000019901 Anxiety disease Diseases 0.000 claims description 39
230000036506 anxiety Effects 0.000 claims description 36
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
239000000203 mixture Substances 0.000 claims description 26
125000000217 alkyl group Chemical group 0.000 claims description 25
230000000949 anxiolytic effect Effects 0.000 claims description 24
125000003118 aryl group Chemical group 0.000 claims description 24
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 24
150000002894 organic compounds Chemical class 0.000 claims description 23
239000002249 anxiolytic agent Substances 0.000 claims description 20
125000002837 carbocyclic group Chemical group 0.000 claims description 20
125000000753 cycloalkyl group Chemical group 0.000 claims description 20
241000700199 Cavia porcellus Species 0.000 claims description 18
241000282414 Homo sapiens Species 0.000 claims description 18
241001465754 Metazoa Species 0.000 claims description 17
229910052739 hydrogen Inorganic materials 0.000 claims description 17
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 15
125000004122 cyclic group Chemical group 0.000 claims description 15
229910052722 tritium Inorganic materials 0.000 claims description 15
229920006395 saturated elastomer Polymers 0.000 claims description 14
230000001747 exhibiting effect Effects 0.000 claims description 13
241000124008 Mammalia Species 0.000 claims description 12
125000002947 alkylene group Chemical group 0.000 claims description 11
125000003710 aryl alkyl group Chemical group 0.000 claims description 11
125000000623 heterocyclic group Chemical group 0.000 claims description 11
239000001257 hydrogen Substances 0.000 claims description 11
206010020772 Hypertension Diseases 0.000 claims description 9
125000004340 exo-2-norbornyl group Chemical group [H]C1([H])C([H])([H])[C@@]2([H])C([H])([H])[C@]1([H])C([H])([H])[C@]2([H])* 0.000 claims description 9
150000002431 hydrogen Chemical class 0.000 claims description 9
208000004547 Hallucinations Diseases 0.000 claims description 8
210000005171 mammalian brain Anatomy 0.000 claims description 7
230000002159 abnormal effect Effects 0.000 claims description 6
230000004064 dysfunction Effects 0.000 claims description 5
238000011321 prophylaxis Methods 0.000 claims description 5
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims description 4
230000003340 mental effect Effects 0.000 claims description 4
239000012736 aqueous medium Substances 0.000 claims description 3
125000001072 heteroaryl group Chemical group 0.000 claims description 3
230000004048 modification Effects 0.000 claims description 3
238000012986 modification Methods 0.000 claims description 3
230000002285 radioactive effect Effects 0.000 claims description 3
SAPQZYMPGUOQOF-UHFFFAOYSA-N 1,2-bis(2-iodophenyl)guanidine Chemical compound IC1=CC=CC=C1NC(=N)NC1=CC=CC=C1I SAPQZYMPGUOQOF-UHFFFAOYSA-N 0.000 claims description 2
VEGSEUJMFASKPM-UHFFFAOYSA-N 1,2-dibenzylguanidine Chemical compound C=1C=CC=CC=1CNC(=N)NCC1=CC=CC=C1 VEGSEUJMFASKPM-UHFFFAOYSA-N 0.000 claims description 2
MPUAUPQFSLHOHQ-UHFFFAOYSA-N 1,2-dicyclohexylguanidine Chemical compound C1CCCCC1NC(=N)NC1CCCCC1 MPUAUPQFSLHOHQ-UHFFFAOYSA-N 0.000 claims description 2
125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 2
125000004341 endo-2-norbornyl group Chemical group [H]C1([H])C([H])([H])[C@@]2([H])C([H])([H])[C@]1([H])C([H])([H])[C@@]2([H])* 0.000 claims 7
JUNBYRXGWOTEEP-UHFFFAOYSA-N [C].NC(N)=N Chemical group [C].NC(N)=N JUNBYRXGWOTEEP-UHFFFAOYSA-N 0.000 claims 5
HKQAANYYOSPWPM-UHFFFAOYSA-N 1,2-bis(1,2,3,4-tetrahydronaphthalen-1-yl)guanidine Chemical compound C1CCC2=CC=CC=C2C1NC(=N)NC1C2=CC=CC=C2CCC1 HKQAANYYOSPWPM-UHFFFAOYSA-N 0.000 claims 4
KTLUTBQGBABJDU-UHFFFAOYSA-N 1,2-bis(3-propylphenyl)guanidine Chemical compound CCCC1=CC=CC(NC(=N)NC=2C=C(CCC)C=CC=2)=C1 KTLUTBQGBABJDU-UHFFFAOYSA-N 0.000 claims 4
JYQMCTXRNGINFZ-UHFFFAOYSA-N 1-(4-bromo-2-methylphenyl)-2-cyclohexylguanidine Chemical compound CC1=CC(Br)=CC=C1NC(=N)NC1CCCCC1 JYQMCTXRNGINFZ-UHFFFAOYSA-N 0.000 claims 4
METBKYNDHDGJGY-UHFFFAOYSA-N 2-(1-adamantyl)-1-(2-nitrophenyl)guanidine Chemical compound [O-][N+](=O)C1=CC=CC=C1NC(=N)NC1(C2)CC(C3)CC2CC3C1 METBKYNDHDGJGY-UHFFFAOYSA-N 0.000 claims 4
HREBFKCZFOECGR-UHFFFAOYSA-N 2-(1-adamantyl)-1-[4-fluoro-2-(trifluoromethyl)phenyl]guanidine Chemical compound FC(F)(F)C1=CC(F)=CC=C1NC(=N)NC1(C2)CC(C3)CC2CC3C1 HREBFKCZFOECGR-UHFFFAOYSA-N 0.000 claims 4
JFRVIRASSXIVLH-UHFFFAOYSA-N 2-tert-butyl-1-(2-iodophenyl)guanidine Chemical compound CC(C)(C)NC(=N)NC1=CC=CC=C1I JFRVIRASSXIVLH-UHFFFAOYSA-N 0.000 claims 4
NOQAGZATBRITDX-UHFFFAOYSA-N 1,2-bis(5-bromo-2-methylphenyl)guanidine Chemical compound CC1=CC=C(Br)C=C1NC(=N)NC1=CC(Br)=CC=C1C NOQAGZATBRITDX-UHFFFAOYSA-N 0.000 claims 3
DZPXQGGBMZBZNI-UHFFFAOYSA-N 1,2-bis[(2-methylphenyl)methyl]guanidine Chemical compound CC1=CC=CC=C1CNC(=N)NCC1=CC=CC=C1C DZPXQGGBMZBZNI-UHFFFAOYSA-N 0.000 claims 3
206010002869 Anxiety symptoms Diseases 0.000 claims 3
DMKHPJQTKYTAQN-UHFFFAOYSA-N 1,3-bis(3-ethylphenyl)imidazolidin-2-imine Chemical compound CCC1=CC=CC(N2C(N(CC2)C=2C=C(CC)C=CC=2)=N)=C1 DMKHPJQTKYTAQN-UHFFFAOYSA-N 0.000 claims 2
FYZGFWOIQSITSW-UHFFFAOYSA-N 1-(5-bromo-2-methylphenyl)-2-cyclohexylguanidine Chemical compound CC1=CC=C(Br)C=C1NC(=N)NC1CCCCC1 FYZGFWOIQSITSW-UHFFFAOYSA-N 0.000 claims 2
AFWDFPQVQNRSJJ-UHFFFAOYSA-N 2-(1-adamantyl)-1-(2,4-difluorophenyl)guanidine Chemical compound FC1=CC(F)=CC=C1NC(=N)NC1(C2)CC(C3)CC2CC3C1 AFWDFPQVQNRSJJ-UHFFFAOYSA-N 0.000 claims 2
XAKPVTYBFUZSJC-UHFFFAOYSA-N 2-(1-adamantyl)-1-(2-propan-2-ylphenyl)guanidine Chemical compound CC(C)C1=CC=CC=C1NC(=N)NC1(C2)CC(C3)CC2CC3C1 XAKPVTYBFUZSJC-UHFFFAOYSA-N 0.000 claims 2
NSOJADJSIOHGHB-UHFFFAOYSA-N 2-(3,5-dimethyl-1-adamantyl)-1-(2-methylphenyl)guanidine Chemical compound CC1=CC=CC=C1NC(=N)NC1(C2)CC(C)(C3)CC2(C)CC3C1 NSOJADJSIOHGHB-UHFFFAOYSA-N 0.000 claims 2
206010037249 Psychotic behaviour Diseases 0.000 claims 2
230000007717 exclusion Effects 0.000 claims 2
230000001631 hypertensive effect Effects 0.000 claims 2
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
CDKJFRLFTVPCDI-UHFFFAOYSA-N 1,2-bis(2,3-dihydro-1h-inden-4-yl)guanidine Chemical compound C=1C=CC=2CCCC=2C=1NC(=N)NC1=CC=CC2=C1CCC2 CDKJFRLFTVPCDI-UHFFFAOYSA-N 0.000 claims 1
RIAXXCQKICATHW-UHFFFAOYSA-N 1,2-bis(3-methylphenyl)guanidine Chemical compound CC1=CC=CC(NC(=N)NC=2C=C(C)C=CC=2)=C1 RIAXXCQKICATHW-UHFFFAOYSA-N 0.000 claims 1
FHMLQOSOQRUWSB-UHFFFAOYSA-N 1,2-bis(tetrazol-1-yl)guanidine Chemical compound C1=NN=NN1N=C(N)NN1C=NN=N1 FHMLQOSOQRUWSB-UHFFFAOYSA-N 0.000 claims 1
PGCGCFBAHRVIIN-UHFFFAOYSA-N 1,3-bis(2-methylphenyl)imidazolidin-2-imine Chemical compound CC1=CC=CC=C1N1C(=N)N(C=2C(=CC=CC=2)C)CC1 PGCGCFBAHRVIIN-UHFFFAOYSA-N 0.000 claims 1
XZGRNYZXYCNDHI-UHFFFAOYSA-N 1-(2-iodophenyl)-2-(2-methylphenyl)guanidine Chemical compound CC1=CC=CC=C1NC(=N)NC1=CC=CC=C1I XZGRNYZXYCNDHI-UHFFFAOYSA-N 0.000 claims 1
WDYCWJKRDHPOMN-UHFFFAOYSA-N 1-(5-bromo-2-methyl-4-nitrophenyl)-2-(4,5-dibromo-2-methylphenyl)guanidine Chemical compound CC1=CC([N+]([O-])=O)=C(Br)C=C1NC(N)=NC1=CC(Br)=C(Br)C=C1C WDYCWJKRDHPOMN-UHFFFAOYSA-N 0.000 claims 1
OAIQPJDIIKAXFX-UHFFFAOYSA-N 2-(1-adamantyl)-1-(4-bromo-2-methylphenyl)guanidine Chemical compound CC1=CC(Br)=CC=C1NC(N)=NC1(C2)CC(C3)CC2CC3C1 OAIQPJDIIKAXFX-UHFFFAOYSA-N 0.000 claims 1
OCUUDHBWYKCRGO-UHFFFAOYSA-N 2-(1-adamantyl)-1-[2-(trifluoromethyl)phenyl]guanidine Chemical compound FC(F)(F)C1=CC=CC=C1NC(=N)NC1(C2)CC(C3)CC2CC3C1 OCUUDHBWYKCRGO-UHFFFAOYSA-N 0.000 claims 1
CGRZIFOWNVWOGQ-UHFFFAOYSA-N 2-(1-adamantyl)-1-methyl-1-(2-methylphenyl)guanidine Chemical compound C1C(C2)CC(C3)CC2CC13NC(=N)N(C)C1=CC=CC=C1C CGRZIFOWNVWOGQ-UHFFFAOYSA-N 0.000 claims 1
AGGSMRWOSSYYHD-UHFFFAOYSA-N 2-(2-adamantyl)-1-(2-iodophenyl)guanidine Chemical compound IC1=CC=CC=C1NC(=N)NC1C(C2)CC3CC2CC1C3 AGGSMRWOSSYYHD-UHFFFAOYSA-N 0.000 claims 1
BQFWRQMKLMLBDM-UHFFFAOYSA-N 2-(2-iodophenyl)-1-naphthalen-1-ylguanidine Chemical compound IC1=CC=CC=C1NC(=N)NC1=CC=CC2=CC=CC=C12 BQFWRQMKLMLBDM-UHFFFAOYSA-N 0.000 claims 1
URIJSKQEDHOILM-UHFFFAOYSA-N 2-(2-methyl-4-nitrophenyl)-1-(2-methylphenyl)guanidine Chemical compound CC1=CC=CC=C1NC(=N)NC1=CC=C([N+]([O-])=O)C=C1C URIJSKQEDHOILM-UHFFFAOYSA-N 0.000 claims 1
OGAVVWZTKYWFNT-UHFFFAOYSA-N 2-(3,5-dimethyl-1-adamantyl)-1-(2-iodophenyl)guanidine Chemical compound C1C(C)(C2)CC(C3)CC1(C)CC32NC(=N)NC1=CC=CC=C1I OGAVVWZTKYWFNT-UHFFFAOYSA-N 0.000 claims 1
WDLSCOFOUSBRKH-UHFFFAOYSA-N 2-(4-azido-2-methylphenyl)-1-(2-methylphenyl)guanidine Chemical compound CC1=CC=CC=C1NC(N)=NC1=CC=C(N=[N+]=[N-])C=C1C WDLSCOFOUSBRKH-UHFFFAOYSA-N 0.000 claims 1
CKLOSYYAFRUXFF-UHFFFAOYSA-N 2-cyclohexyl-1-(4-iodophenyl)guanidine Chemical compound C1=CC(I)=CC=C1NC(=N)NC1CCCCC1 CKLOSYYAFRUXFF-UHFFFAOYSA-N 0.000 claims 1
HIKWVLDGBVMKQK-UHFFFAOYSA-N CC1=CC=C(Br)C=C1NC(=N)NC1(C2)CC(C3)CC2CC3C1 Chemical compound CC1=CC=C(Br)C=C1NC(=N)NC1(C2)CC(C3)CC2CC3C1 HIKWVLDGBVMKQK-UHFFFAOYSA-N 0.000 claims 1
239000002552 dosage form Substances 0.000 claims 1
229960004198 guanidine Drugs 0.000 description 77
239000003814 drug Substances 0.000 description 72
238000012360 testing method Methods 0.000 description 71
229940079593 drug Drugs 0.000 description 70
239000000243 solution Substances 0.000 description 43
230000000694 effects Effects 0.000 description 41
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 36
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 29
230000006399 behavior Effects 0.000 description 29
241000699666 Mus <mouse, genus> Species 0.000 description 28
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
241000699670 Mus sp. Species 0.000 description 24
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
239000007787 solid Substances 0.000 description 24
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
241000700159 Rattus Species 0.000 description 22
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 22
239000002244 precipitate Substances 0.000 description 19
239000000932 sedative agent Substances 0.000 description 19
230000001624 sedative effect Effects 0.000 description 19
238000006243 chemical reaction Methods 0.000 description 18
229960003878 haloperidol Drugs 0.000 description 18
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 17
239000011541 reaction mixture Substances 0.000 description 17
230000015572 biosynthetic process Effects 0.000 description 16
230000007423 decrease Effects 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
239000000047 product Substances 0.000 description 15
239000000725 suspension Substances 0.000 description 15
238000003786 synthesis reaction Methods 0.000 description 15
238000001914 filtration Methods 0.000 description 14
230000001965 increasing effect Effects 0.000 description 14
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 14
238000002360 preparation method Methods 0.000 description 14
230000000875 corresponding effect Effects 0.000 description 13
229940005483 opioid analgesics Drugs 0.000 description 13
230000002385 psychotomimetic effect Effects 0.000 description 13
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
239000005557 antagonist Substances 0.000 description 12
239000000164 antipsychotic agent Substances 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 12
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 12
238000000338 in vitro Methods 0.000 description 12
239000003446 ligand Substances 0.000 description 12
230000003389 potentiating effect Effects 0.000 description 12
239000007983 Tris buffer Substances 0.000 description 11
230000003542 behavioural effect Effects 0.000 description 11
229960003638 dopamine Drugs 0.000 description 11
238000001727 in vivo Methods 0.000 description 11
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 11
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
238000003089 Pariser Parr Pople method Methods 0.000 description 10
229920000265 Polyparaphenylene Polymers 0.000 description 10
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 10
230000000561 anti-psychotic effect Effects 0.000 description 10
229960003529 diazepam Drugs 0.000 description 10
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
239000013259 porous coordination polymer Substances 0.000 description 10
238000010992 reflux Methods 0.000 description 10
102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 9
238000005481 NMR spectroscopy Methods 0.000 description 9
238000003556 assay Methods 0.000 description 9
150000002990 phenothiazines Chemical class 0.000 description 9
230000004044 response Effects 0.000 description 9
125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 description 8
102000015554 Dopamine receptor Human genes 0.000 description 8
108050004812 Dopamine receptor Proteins 0.000 description 8
229940049706 benzodiazepine Drugs 0.000 description 8
150000001557 benzodiazepines Chemical class 0.000 description 8
231100000673 dose–response relationship Toxicity 0.000 description 8
230000009870 specific binding Effects 0.000 description 8
125000001424 substituent group Chemical group 0.000 description 8
VVFVRTNNLLZXAL-UHFFFAOYSA-N 2-(2-methylphenyl)guanidine Chemical compound CC1=CC=CC=C1N=C(N)N VVFVRTNNLLZXAL-UHFFFAOYSA-N 0.000 description 7
102000003840 Opioid Receptors Human genes 0.000 description 7
108090000137 Opioid Receptors Proteins 0.000 description 7
239000000872 buffer Substances 0.000 description 7
239000002775 capsule Substances 0.000 description 7
238000006073 displacement reaction Methods 0.000 description 7
229940127240 opiate Drugs 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
241000282412 Homo Species 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
238000010171 animal model Methods 0.000 description 6
229940030600 antihypertensive agent Drugs 0.000 description 6
239000002220 antihypertensive agent Substances 0.000 description 6
238000012512 characterization method Methods 0.000 description 6
238000001816 cooling Methods 0.000 description 6
238000009826 distribution Methods 0.000 description 6
229920001971 elastomer Polymers 0.000 description 6
239000000284 extract Substances 0.000 description 6
239000012458 free base Substances 0.000 description 6
102000048260 kappa Opioid Receptors Human genes 0.000 description 6
239000007788 liquid Substances 0.000 description 6
102000051367 mu Opioid Receptors Human genes 0.000 description 6
230000000144 pharmacologic effect Effects 0.000 description 6
238000000159 protein binding assay Methods 0.000 description 6
239000005060 rubber Substances 0.000 description 6
201000000980 schizophrenia Diseases 0.000 description 6
239000002904 solvent Substances 0.000 description 6
108020001588 κ-opioid receptors Proteins 0.000 description 6
108020001612 μ-opioid receptors Proteins 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000009471 action Effects 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 5
229960004046 apomorphine Drugs 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
235000019439 ethyl acetate Nutrition 0.000 description 5
238000010438 heat treatment Methods 0.000 description 5
238000011534 incubation Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
239000000843 powder Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
UQYYBDRECPZRSP-UHFFFAOYSA-N 1-adamantylcyanamide Chemical compound C1C(C2)CC3CC2CC1(NC#N)C3 UQYYBDRECPZRSP-UHFFFAOYSA-N 0.000 description 4
238000005160 1H NMR spectroscopy Methods 0.000 description 4
GUDVQJXODNJRIJ-CALCHBBNSA-N 9-[3-[(3S,5R)-3,5-dimethyl-1-piperazinyl]propyl]carbazole Chemical compound C1[C@@H](C)N[C@@H](C)CN1CCCN1C2=CC=CC=C2C2=CC=CC=C21 GUDVQJXODNJRIJ-CALCHBBNSA-N 0.000 description 4
101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 4
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
229960004373 acetylcholine Drugs 0.000 description 4
125000004423 acyloxy group Chemical group 0.000 description 4
125000003545 alkoxy group Chemical group 0.000 description 4
125000003282 alkyl amino group Chemical group 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000000538 analytical sample Substances 0.000 description 4
229940005530 anxiolytics Drugs 0.000 description 4
238000009835 boiling Methods 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000013078 crystal Substances 0.000 description 4
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 4
108700023159 delta Opioid Receptors Proteins 0.000 description 4
102000048124 delta Opioid Receptors Human genes 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000003365 glass fiber Substances 0.000 description 4
229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 4
230000003400 hallucinatory effect Effects 0.000 description 4
150000002430 hydrocarbons Chemical group 0.000 description 4
238000002372 labelling Methods 0.000 description 4
238000005259 measurement Methods 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 4
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 4
229960004127 naloxone Drugs 0.000 description 4
210000003739 neck Anatomy 0.000 description 4
230000009871 nonspecific binding Effects 0.000 description 4
RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 4
239000008188 pellet Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
230000002265 prevention Effects 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000006722 reduction reaction Methods 0.000 description 4
229950004933 rimcazole Drugs 0.000 description 4
239000000523 sample Substances 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
238000003756 stirring Methods 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 description 3
OPNUROKCUBTKLF-UHFFFAOYSA-N 1,2-bis(2-methylphenyl)guanidine Chemical compound CC1=CC=CC=C1N\C(N)=N\C1=CC=CC=C1C OPNUROKCUBTKLF-UHFFFAOYSA-N 0.000 description 3
OWRCNXZUPFZXOS-UHFFFAOYSA-N 1,3-diphenylguanidine Chemical compound C=1C=CC=CC=1NC(=N)NC1=CC=CC=C1 OWRCNXZUPFZXOS-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Natural products C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
241000662429 Fenerbahce Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
238000001792 White test Methods 0.000 description 3
239000000556 agonist Substances 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
239000003443 antiviral agent Substances 0.000 description 3
230000003925 brain function Effects 0.000 description 3
210000005013 brain tissue Anatomy 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
229950002213 cyclazocine Drugs 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Substances CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
229940043279 diisopropylamine Drugs 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 3
229950004155 etorphine Drugs 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000007789 gas Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
229960001404 quinidine Drugs 0.000 description 3
239000002287 radioligand Substances 0.000 description 3
238000011160 research Methods 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
230000000698 schizophrenic effect Effects 0.000 description 3
230000003997 social interaction Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
238000004611 spectroscopical analysis Methods 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000003826 tablet Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
238000005406 washing Methods 0.000 description 3
DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
FFTTVUHJOUFETK-UHFFFAOYSA-N 1,2-bis(1-adamantyl)guanidine Chemical compound C1C(C2)CC(C3)CC2CC13N=C(N)NC1(C2)CC(C3)CC2CC3C1 FFTTVUHJOUFETK-UHFFFAOYSA-N 0.000 description 2
HXEJAEDEMWCUTP-UHFFFAOYSA-N 1,2-dibutylguanidine Chemical compound CCCCNC(=N)NCCCC HXEJAEDEMWCUTP-UHFFFAOYSA-N 0.000 description 2
ZXUYYZPJUGQHLQ-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]-1-butanol Chemical compound C=1C=C(F)C=CC=1C(O)CCCN(CC1)CCN1C1=NC=C(F)C=N1 ZXUYYZPJUGQHLQ-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
HTSNFXAICLXZMA-UHFFFAOYSA-N 3-(1-propyl-3-piperidinyl)phenol Chemical compound C1N(CCC)CCCC1C1=CC=CC(O)=C1 HTSNFXAICLXZMA-UHFFFAOYSA-N 0.000 description 2
JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 2
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
241000995051 Brenda Species 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
241000700198 Cavia Species 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
208000020401 Depressive disease Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
229910004809 Na2 SO4 Inorganic materials 0.000 description 2
108010063843 Phencyclidine Receptors Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
230000003276 anti-hypertensive effect Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
239000006286 aqueous extract Substances 0.000 description 2
239000008135 aqueous vehicle Substances 0.000 description 2
230000002567 autonomic effect Effects 0.000 description 2
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000004305 biphenyl Substances 0.000 description 2
210000001772 blood platelet Anatomy 0.000 description 2
239000012267 brine Substances 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
229960002495 buspirone Drugs 0.000 description 2
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
150000001716 carbazoles Chemical class 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000001055 chewing effect Effects 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
229960001076 chlorpromazine Drugs 0.000 description 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
238000004891 communication Methods 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
239000002131 composite material Substances 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
239000012043 crude product Substances 0.000 description 2
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000004821 distillation Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000008298 dragée Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
235000013305 food Nutrition 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
229960003692 gamma aminobutyric acid Drugs 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
210000004884 grey matter Anatomy 0.000 description 2
BPMFZUMJYQTVII-UHFFFAOYSA-N guanidinoacetic acid Chemical compound NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
125000004356 hydroxy functional group Chemical group O* 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
150000002513 isocyanates Chemical class 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000002197 limbic effect Effects 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
230000037023 motor activity Effects 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
210000001577 neostriatum Anatomy 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
239000002957 persistent organic pollutant Substances 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
125000003373 pyrazinyl group Chemical group 0.000 description 2
238000001525 receptor binding assay Methods 0.000 description 2
238000013391 scatchard analysis Methods 0.000 description 2
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
229960002646 scopolamine Drugs 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
230000035939 shock Effects 0.000 description 2
239000003982 sigma receptor ligand Substances 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000002002 slurry Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000000707 stereoselective effect Effects 0.000 description 2
101150035983 str1 gene Proteins 0.000 description 2
239000000829 suppository Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000009492 tablet coating Methods 0.000 description 2
239000002700 tablet coating Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
230000007704 transition Effects 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
229910052721 tungsten Inorganic materials 0.000 description 2
239000005526 vasoconstrictor agent Substances 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
ZTGMHFIGNYXMJV-SQTRZTOVSA-N (1R)-1,13-dimethyl-10-prop-2-enyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol hydrochloride Chemical compound CC1C2CC3=C([C@@]1(CCN2CC=C)C)C=C(C=C3)O.Cl ZTGMHFIGNYXMJV-SQTRZTOVSA-N 0.000 description 1
DRBLTDRGXNXHFZ-UHFFFAOYSA-N (2-methylphenyl)cyanamide Chemical compound CC1=CC=CC=C1NC#N DRBLTDRGXNXHFZ-UHFFFAOYSA-N 0.000 description 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
XZBCEESOMMQJJD-UHFFFAOYSA-N 1,1-dichlorocyclopentane Chemical compound ClC1(Cl)CCCC1 XZBCEESOMMQJJD-UHFFFAOYSA-N 0.000 description 1
CUKVUPVXXDMUFY-UHFFFAOYSA-N 1,2-bis(4-iodo-2-methylphenyl)guanidine Chemical compound CC1=CC(I)=CC=C1NC(=N)NC1=CC=C(I)C=C1C CUKVUPVXXDMUFY-UHFFFAOYSA-N 0.000 description 1
YNROXQFWCCJXEG-UHFFFAOYSA-N 1,2-dimethyl-1-phenylguanidine Chemical compound CN=C(N)N(C)C1=CC=CC=C1 YNROXQFWCCJXEG-UHFFFAOYSA-N 0.000 description 1
WWXQUCZWYIQLTJ-UHFFFAOYSA-N 1-(1-adamantyl)-1-(2-methylphenyl)guanidine Chemical compound CC1=CC=CC=C1N(C(N)=N)C1(C2)CC(C3)CC2CC3C1 WWXQUCZWYIQLTJ-UHFFFAOYSA-N 0.000 description 1
OXFVFQRCEDQAND-UHFFFAOYSA-N 1-ethyl-1-octylguanidine Chemical class C(C)N(C(=N)N)CCCCCCCC OXFVFQRCEDQAND-UHFFFAOYSA-N 0.000 description 1
YUEATNYGWBDCEL-UHFFFAOYSA-N 1-hydroxypropyl carbamate Chemical class CCC(O)OC(N)=O YUEATNYGWBDCEL-UHFFFAOYSA-N 0.000 description 1
DSJVSLJDQPTJSK-UHFFFAOYSA-N 1-methyl-1-phenylguanidine Chemical compound NC(=N)N(C)C1=CC=CC=C1 DSJVSLJDQPTJSK-UHFFFAOYSA-N 0.000 description 1
VPVFRBVISRPGTF-UHFFFAOYSA-N 1-phenyl-1-pyridin-2-ylguanidine Chemical compound C1(=CC=CC=C1)N(C(=N)N)C1=NC=CC=C1 VPVFRBVISRPGTF-UHFFFAOYSA-N 0.000 description 1
WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
CXFLGSOEVKCMNO-UHFFFAOYSA-N 2-(1-adamantyl)-1-(2-phenylphenyl)guanidine Chemical compound C1C(C2)CC(C3)CC2CC13NC(=N)NC1=CC=CC=C1C1=CC=CC=C1 CXFLGSOEVKCMNO-UHFFFAOYSA-N 0.000 description 1
MXDAOHAPVWZSQU-UHFFFAOYSA-N 2-(2-aminoethyl)guanidine Chemical class NCCNC(N)=N MXDAOHAPVWZSQU-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
PVTRCZCFBBXXQG-UHFFFAOYSA-N 2-(3-phenylprop-2-enyl)guanidine Chemical class NC(N)=NCC=CC1=CC=CC=C1 PVTRCZCFBBXXQG-UHFFFAOYSA-N 0.000 description 1
YYUKMPXTCMMQMY-UHFFFAOYSA-N 2-(4-amino-2-methylphenyl)-1-(2-methylphenyl)guanidine Chemical compound CC1=CC=CC=C1NC(=N)NC1=CC=C(N)C=C1C YYUKMPXTCMMQMY-UHFFFAOYSA-N 0.000 description 1
IQGKMQSGJFTJLF-UHFFFAOYSA-N 2-(4-bromo-2-methylphenyl)guanidine Chemical compound CC1=CC(Br)=CC=C1NC(N)=N IQGKMQSGJFTJLF-UHFFFAOYSA-N 0.000 description 1
125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
LGGPGRCUXWQIDU-UHFFFAOYSA-N 2-[(2-methylphenyl)methyl]guanidine Chemical compound CC1=CC=CC=C1CN=C(N)N LGGPGRCUXWQIDU-UHFFFAOYSA-N 0.000 description 1
IXZXFWYQKMZGJR-UHFFFAOYSA-N 2-[2-(trifluoromethyl)phenyl]guanidine Chemical compound NC(=N)NC1=CC=CC=C1C(F)(F)F IXZXFWYQKMZGJR-UHFFFAOYSA-N 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
JPGMSPJHRKUMDF-UHFFFAOYSA-N 2-propoxyguanidine Chemical class CCCONC(N)=N JPGMSPJHRKUMDF-UHFFFAOYSA-N 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
PCHYYOCUCGCSBU-UHFFFAOYSA-N 4-bromo-2-methylaniline Chemical compound CC1=CC(Br)=CC=C1N PCHYYOCUCGCSBU-UHFFFAOYSA-N 0.000 description 1
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
LRCQLCWUUBSUOY-UHFFFAOYSA-N 4-fluoro-2-(trifluoromethyl)aniline Chemical compound NC1=CC=C(F)C=C1C(F)(F)F LRCQLCWUUBSUOY-UHFFFAOYSA-N 0.000 description 1
102000035038 5-HT1 receptors Human genes 0.000 description 1
108091005478 5-HT1 receptors Proteins 0.000 description 1
JNYLMODTPLSLIF-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-carboxylic acid Chemical group OC(=O)C1=CC=C(C(F)(F)F)N=C1 JNYLMODTPLSLIF-UHFFFAOYSA-N 0.000 description 1
JMHFFDIMOUKDCZ-NTXHZHDSSA-N 61214-51-5 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 JMHFFDIMOUKDCZ-NTXHZHDSSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
102100033938 AP-1 complex subunit gamma-1 Human genes 0.000 description 1
206010000117 Abnormal behaviour Diseases 0.000 description 1
108010059616 Activins Proteins 0.000 description 1
206010001557 Albinism Diseases 0.000 description 1
241000270728 Alligator Species 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
208000031295 Animal disease Diseases 0.000 description 1
241000156724 Antirhea Species 0.000 description 1
241001106067 Atropa Species 0.000 description 1
102000007527 Autoreceptors Human genes 0.000 description 1
108010071131 Autoreceptors Proteins 0.000 description 1
102400000748 Beta-endorphin Human genes 0.000 description 1
101800005049 Beta-endorphin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000036632 Brain mass Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000009132 Catalepsy Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
WGJWHHPFRRKPJJ-UHFFFAOYSA-N ClC(=O)O.C(C(=O)O)(=O)O Chemical compound ClC(=O)O.C(C(=O)O)(=O)O WGJWHHPFRRKPJJ-UHFFFAOYSA-N 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
102100021790 Delta-sarcoglycan Human genes 0.000 description 1
208000006558 Dental Calculus Diseases 0.000 description 1
208000032538 Depersonalisation Diseases 0.000 description 1
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
101100365800 Drosophila melanogaster sima gene Proteins 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
241001149925 Fenneropenaeus indicus Species 0.000 description 1
PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
208000011688 Generalised anxiety disease Diseases 0.000 description 1
244000043261 Hevea brasiliensis Species 0.000 description 1
101000779234 Homo sapiens AP-1 complex subunit gamma-1 Proteins 0.000 description 1
101000616408 Homo sapiens Delta-sarcoglycan Proteins 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100026818 Inhibin beta E chain Human genes 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
ZZJYIKPMDIWRSN-HWBMXIPRSA-N LSM-20934 Chemical compound C12=CC=CC=C2CCC2=CC=CC3=C2[C@H]1CN1CC[C@](C(C)(C)C)(O)C[C@H]13 ZZJYIKPMDIWRSN-HWBMXIPRSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000877 Melamine resin Polymers 0.000 description 1
101100206738 Mus musculus Tiam2 gene Proteins 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
208000006550 Mydriasis Diseases 0.000 description 1
229910001199 N alloy Inorganic materials 0.000 description 1
PMDCZENCAXMSOU-UHFFFAOYSA-N N-ethylacetamide Chemical class CCNC(C)=O PMDCZENCAXMSOU-UHFFFAOYSA-N 0.000 description 1
JYGSLYDLTXQMCI-UHFFFAOYSA-N N1N=CC=CC=C1.NC(=N)N Chemical compound N1N=CC=CC=C1.NC(=N)N JYGSLYDLTXQMCI-UHFFFAOYSA-N 0.000 description 1
KKMUFFMWKCOPQQ-NYXPYYKPSA-N O[C@H]([C@@H]1O2)C=C[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(ONC(N)=N)=CC=C1C4 Chemical compound O[C@H]([C@@H]1O2)C=C[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(ONC(N)=N)=CC=C1C4 KKMUFFMWKCOPQQ-NYXPYYKPSA-N 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
108010093625 Opioid Peptides Proteins 0.000 description 1
102000001490 Opioid Peptides Human genes 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
241000336676 Pelia Species 0.000 description 1
RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
206010034912 Phobia Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 1
241000288906 Primates Species 0.000 description 1
102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
108010059712 Pronase Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
241001080189 Quadrus Species 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000000219 Sympatholytic Substances 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical class C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
206010047853 Waxy flexibility Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000488 activin Substances 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
229920000180 alkyd Polymers 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940124277 aminobutyric acid Drugs 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
208000036878 aneuploidy Diseases 0.000 description 1
231100001075 aneuploidy Toxicity 0.000 description 1
MMCPOSDMTGQNKG-UHFFFAOYSA-N anilinium chloride Chemical compound Cl.NC1=CC=CC=C1 MMCPOSDMTGQNKG-UHFFFAOYSA-N 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
210000003740 anterior thalamic nuclei Anatomy 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
229940124604 anti-psychotic medication Drugs 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
230000000338 anxiogenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
201000000751 autosomal recessive congenital ichthyosis Diseases 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
238000009227 behaviour therapy Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
244000309464 bull Species 0.000 description 1
229950006479 butaclamol Drugs 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
BWOVZCWSJFYBRM-UHFFFAOYSA-N carbononitridic isocyanate Chemical compound O=C=NC#N BWOVZCWSJFYBRM-UHFFFAOYSA-N 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000010531 catalytic reduction reaction Methods 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229960003260 chlorhexidine Drugs 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
210000003477 cochlea Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004590 computer program Methods 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
230000009193 crawling Effects 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
230000000515 cyanogenic effect Effects 0.000 description 1
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000013872 defecation Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
229960003914 desipramine Drugs 0.000 description 1
238000003795 desorption Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
239000011903 deuterated solvents‎ Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
229910001651 emery Inorganic materials 0.000 description 1
239000006274 endogenous ligand Substances 0.000 description 1
208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
125000003700 epoxy group Chemical group 0.000 description 1
DLLJVQNYBYOKGS-UHFFFAOYSA-N ethoxyethane;pentane Chemical compound CCCCC.CCOCC DLLJVQNYBYOKGS-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000005284 excitation Effects 0.000 description 1
210000000256 facial nerve Anatomy 0.000 description 1
150000002194 fatty esters Chemical class 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
238000009472 formulation Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
239000003457 ganglion blocking agent Substances 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
208000037870 generalized anxiety Diseases 0.000 description 1
208000029364 generalized anxiety disease Diseases 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
230000026781 habituation Effects 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
229950002932 hexamethonium Drugs 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
230000000742 histaminergic effect Effects 0.000 description 1
239000010903 husk Substances 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
229940126904 hypoglycaemic agent Drugs 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229940125425 inverse agonist Drugs 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000006303 iodophenyl group Chemical group 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
229960004592 isopropanol Drugs 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
230000006651 lactation Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
CSEQZSFFKQUJAQ-UHFFFAOYSA-N lithium 1-adamantylazanide Chemical compound C12(CC3CC(CC(C1)C3)C2)[NH-].[Li+] CSEQZSFFKQUJAQ-UHFFFAOYSA-N 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000000627 locus coeruleus Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
208000024714 major depressive disease Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960001300 metoprolol tartrate Drugs 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
230000003551 muscarinic effect Effects 0.000 description 1
230000036640 muscle relaxation Effects 0.000 description 1
210000003249 myenteric plexus Anatomy 0.000 description 1
CURJNMSGPBXOGK-UHFFFAOYSA-N n',n'-di(propan-2-yl)ethane-1,2-diamine Chemical compound CC(C)N(C(C)C)CCN CURJNMSGPBXOGK-UHFFFAOYSA-N 0.000 description 1
OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
229920003052 natural elastomer Polymers 0.000 description 1
229920001194 natural rubber Polymers 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
230000003565 oculomotor Effects 0.000 description 1
239000003402 opiate agonist Substances 0.000 description 1
239000003399 opiate peptide Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
238000010422 painting Methods 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000000590 parasiticidal effect Effects 0.000 description 1
239000002297 parasiticide Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
229960000762 perphenazine Drugs 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
229950000688 phenothiazine Drugs 0.000 description 1
235000008729 phenylalanine Nutrition 0.000 description 1
150000002994 phenylalanines Chemical class 0.000 description 1
208000019899 phobic disease Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
238000005222 photoaffinity labeling Methods 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
229940001470 psychoactive drug Drugs 0.000 description 1
230000001003 psychopharmacologic effect Effects 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
238000004080 punching Methods 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000005067 remediation Methods 0.000 description 1
230000002940 repellent Effects 0.000 description 1
239000005871 repellent Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
210000001202 rhombencephalon Anatomy 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
230000011273 social behavior Effects 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
210000001679 solitary nucleus Anatomy 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
239000012453 solvate Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000000714 subcommissural organ Anatomy 0.000 description 1
238000000859 sublimation Methods 0.000 description 1
230000008022 sublimation Effects 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
230000000948 sympatholitic effect Effects 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
239000003760 tallow Substances 0.000 description 1
WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
LGQCVMYAEFTEFN-DQYPLSBCSA-N tocris-1079 Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)[C@H](C)[C@H]1N(CC=C)CC2 LGQCVMYAEFTEFN-DQYPLSBCSA-N 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
PYIHTIJNCRKDBV-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCC[N+](C)(C)C PYIHTIJNCRKDBV-UHFFFAOYSA-L 0.000 description 1
238000001665 trituration Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
239000010937 tungsten Substances 0.000 description 1
206010061393 typhus Diseases 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000004073 vulcanization Methods 0.000 description 1
210000002268 wool Anatomy 0.000 description 1